InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing small molecule drug candidates that target CB1/CB2 receptors for Alzheimer's disease, ocular conditions like dry age-related macular degeneration, and dermatological indications. The company is merging with Mentari Therapeutics to advance migraine prevention therapies.